Otsuka
Updates & Highlights
BioWorld News · 5 days ago
Otsuka’s Simtriyo nod: Qelbree vs. three in ADHD?
simplywall.st · 5 days ago
The Bull Case For Otsuka Holdings (TSE:4578) Could Change Following Upgraded 2026 Earnings Guidance - Learn Why
marketscreener.com · 5 days ago
Otsuka Holdings Co., Ltd. Revises Consolidated Earnings Guidance for the First Half Ending June 30, 2026
Recent Openings
View all 2 jobs arrow_forwardAll Jobs
Culture & Mission
Benefits & Perks
Equity/Stock Options
Ownership in the company
Health Insurance
Medical, dental & vision
Learning Budget
Professional development
Generous PTO
Paid time off
Competitive Salary
Market-rate compensation
Remote Work
Work from anywhere flexibility
Tech Stack
Core Values
Innovation
Pushing boundaries in AI/ML technology
Collaboration
Working together to achieve more
Excellence
Striving for the highest quality
Impact
Making a difference in the world
Office Locations
Team
Are you on the team at Otsuka?
Claim this company page to verify ownership, edit details, and respond to applicants.
Claim this company arrow_forwardNews & Press
20 recentOtsuka’s Simtriyo nod: Qelbree vs. three in ADHD?
Otsuka’s Simtriyo nod: Qelbree vs. three in ADHD?
BioWorld News · 5 days ago
The Bull Case For Otsuka Holdings (TSE:4578) Could Change Following Upgraded 2026 Earnings Guidance - Learn Why
The Bull Case For Otsuka Holdings (TSE:4578) Could Change Following Upgraded 2026 Earnings Guidance - Learn Why
simplywall.st · 5 days ago
Otsuka Holdings Co., Ltd. Revises Consolidated Earnings Guidance for the First Half Ending June 30, 2026
Otsuka Holdings Co., Ltd. Revises Consolidated Earnings Guidance for the First Half Ending June 30, 2026
marketscreener.com · 5 days ago
Otsuka to Present Pivotal Two-Year eGFR Results from the Phase 3 VISIONARY Trial of VOYXACT® (sibeprenlimab-szsi) in IgA Nephropathy (IgAN) at GlomCon Hawaii 2026
Otsuka to Present Pivotal Two-Year eGFR Results from the Phase 3 VISIONARY Trial of VOYXACT® (sibeprenlimab-szsi) in IgA Nephropathy (IgAN) at GlomCon Hawaii 2026
BioSpace · 5 days ago
TABLE-Otsuka Holdings Co Ltd -2026 6-month group forecast(IFRS)
TABLE-Otsuka Holdings Co Ltd -2026 6-month group forecast(IFRS)
TradingView · 5 days ago
FDA approves Otsuka’s ADHD drug Simtriyo, teeing up its ‘next major CNS launch’
FDA approves Otsuka’s ADHD drug Simtriyo, teeing up its ‘next major CNS launch’
Fierce Pharma · 6 days ago
Yarrow to begin trading as it targets Graves; FDA approves Otsuka’s ADHD pill
Yarrow to begin trading as it targets Graves; FDA approves Otsuka’s ADHD pill
Endpoints News · 6 days ago
FDA Approves Otsuka’s First-In-Class Simtriyo for Adults & Pediatric Patients
FDA Approves Otsuka’s First-In-Class Simtriyo for Adults & Pediatric Patients
Pharmaceutical Executive · 6 days ago
Otsuka’s ADHD approval opens up new drug class with $615M opportunity
Otsuka’s ADHD approval opens up new drug class with $615M opportunity
BioSpace · 6 days ago
Otsuka Launches POCARI SWEAT ION WATER Powder Stick Packet to Make 500mlEasy Water and Ion Replenishment for Day-to-Day Situations: Ideal for Use with Reusable Bottles｜July 27, 2026｜News Releases | Otsuka Pharmaceutical Co., Ltd.
Otsuka Launches POCARI SWEAT ION WATER Powder Stick Packet to Make 500mlEasy Water and Ion Replenishment for Day-to-Day Situations: Ideal for Use with Reusable Bottles｜July 27, 2026｜News Releases | Otsuka Pharmaceutic...
otsuka.co.jp · 6 days ago
Otsuka's triple reuptake inhibitor Simtriyo wins FDA OK for ADHD
Otsuka's triple reuptake inhibitor Simtriyo wins FDA OK for ADHD
FirstWord Pharma · 6 days ago
Otsuka Receives FDA Approval for First-in-Class SIMTRIYO® (centanafadine) for the Treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in Adults and Pediatric Patients Aged 6 Years and Older
Otsuka Receives FDA Approval for First-in-Class SIMTRIYO® (centanafadine) for the Treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in Adults and Pediatric Patients Aged 6 Years and Older
mykxlg.com · 8 days ago
Otsuka Receives FDA Approval for First-in-Class SIMTRIYO® (centanafadine) for the Treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in Adults and Pediatric Patients Aged 6 Years and Older
Otsuka Receives FDA Approval for First-in-Class SIMTRIYO® (centanafadine) for the Treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in Adults and Pediatric Patients Aged 6 Years and Older
Yahoo Finance · 8 days ago
Appeals Court Delays Harper, Otsuka Reinstatement Bid; Trump Administration Ordered To Respond
Appeals Court Delays Harper, Otsuka Reinstatement Bid; Trump Administration Ordered To Respond
CU Today · 9 days ago
Interview: The Apothecary Diaries’ Aoi Yuki and Takeo Otsuka Talk Chemistry and Finding the Essence of Maomao and Jinshi
Interview: The Apothecary Diaries’ Aoi Yuki and Takeo Otsuka Talk Chemistry and Finding the Essence of Maomao and Jinshi
Anime Trending · 9 days ago
D.C. Circuit Court Defers Harper and Otsuka's Motion to Fast-Track Their Appeal
D.C. Circuit Court Defers Harper and Otsuka's Motion to Fast-Track Their Appeal
Credit Union Times · 9 days ago
Jefferies Adjusts Otsuka Holdings' Price Target to 12,700 Yen From 12,500 Yen, Keeps at Buy
Jefferies Adjusts Otsuka Holdings' Price Target to 12,700 Yen From 12,500 Yen, Keeps at Buy
Moomoo · 10 days ago
Enterprise value to EBIT forward of Otsuka Holdings Co., Ltd. – FWB:OS1
Enterprise value to EBIT forward of Otsuka Holdings Co., Ltd. – FWB:OS1
TradingView · 12 days ago
Enterprise value to revenue forward of Otsuka Holdings Co., Ltd. – FWB:OS1
Enterprise value to revenue forward of Otsuka Holdings Co., Ltd. – FWB:OS1
TradingView · 13 days ago
Otsuka ICU Medical outlays $500m to expand US manufacturing footprint
Otsuka ICU Medical outlays $500m to expand US manufacturing footprint
Yahoo Finance · 23 days ago